Medical Oncology

, Volume 29, Issue 3, pp 1656–1662

Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival

Original Paper

Abstract

A platinum-based two-drug regimen is currently the standard of care for patients with advanced non-small-cell lung cancer (NSCLC). However, chemotherapy-induced side effects still remain a significant clinical problem. Astragalus polysaccharide (APS) is a polysaccharide isolated from the radix of astragalus membranaceus, a commonly used herbal compound in traditional Chinese medicine. APS was reported to increase tumor response, stabilize and improve performance status, and reduce chemotherapy toxicity. We designed this trial to determine whether APS injection integrated with vinorelbine and cisplatin (VC) offered an improved QOL over VC for patients with advanced NSCLC. Secondary objectives were tumor response, toxicity, and survival results. One hundred thirty-six patients with histologically or cytologically confirmed NSCLC were enrolled in this study from May 2008 to March 2010. Patients were randomized to receive either VC (VC arm) or VC combined with APS (VC-APS arm). The objective response rate of was 42.64% in the VC-APS arm and 36.76% in the VC arm. The difference was not statistically significant (P = 0.483). Median survival time was 10.7 and 10.2 months (P = 0.76) in VC-APS arm and VC arm, with 1-year survival rates of 35.3 and 32.4% (P = 0.717), respectively. After 3 cycles of treatment, there were significant differences in the overall patient QOL (P = 0.003), physical function (P = 0.01), fatigue (P < 0.001), nausea and vomiting (P < 0.001), pain (P = 0.007), and loss of appetite (P = 0.023) between the two study groups. In summary, we have proved that the treatment of APS integrated with VC had significantly improved QOL in patients with advanced NSCLC compared with VC alone.

Keywords

Non-small cell lung cancer Quality of life Chemotherapy Side effects Astragalus polysaccharide 

References

  1. 1.
    Chen W, Zhang S, Zou X. Estimation and projection of lung cancer incidence and mortality in China. Zhongguo Fei Ai Za Zhi. 2010;13(5):488–93.PubMedGoogle Scholar
  2. 2.
    Rajeswaran A, Trojan A, Burnand B, et al. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer. 2008;59(1):1–11.PubMedCrossRefGoogle Scholar
  3. 3.
    Vilmar A, Santoni-Rugiu E, Sørensen JB. ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer. 2010;46(9):1554–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Adamsen L, Quist M, Midtgaard J, et al. The effect of a multidimensional exercise intervention on physical capacity, well-being and quality of life in cancer patients undergoing chemotherapy. Support Care Cancer. 2006;14(2):116–27.PubMedCrossRefGoogle Scholar
  5. 5.
    Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94.PubMedGoogle Scholar
  6. 6.
    Wu P, Dugoua JJ, Eyawo O, et al. Traditional Chinese medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis. J Exp Clin Cancer Res. 2009;28:112.PubMedCrossRefGoogle Scholar
  7. 7.
    Liu QY, Yao YM, Yu Y, et al. Astragalus polysaccharides attenuate postburn sepsis via inhibiting negative immunoregulation of CD4+ CD25(high) T cells. PLoS One. 2011;6(6):e19811.PubMedCrossRefGoogle Scholar
  8. 8.
    Chen W, Li YM, Yu MH. Astragalus polysaccharides inhibited diabetic cardiomyopathy in hamsters depending on suppression of heart chymase activation. J Diabetes Complicat. 2010;24(3):199–208.PubMedCrossRefGoogle Scholar
  9. 9.
    Ben-Arye E, Attias S, Tadmor T, et al. Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions. Leuk Lymphoma. 2010;51(8):1414–23.PubMedCrossRefGoogle Scholar
  10. 10.
    Tin MM, Cho CH, Chan K, et al. Astragalus saponins induce growth inhibition and apoptosis in human colon cancer cells and tumor xenograft. Carcinogenesis. 2007;28(6):1347–55.PubMedCrossRefGoogle Scholar
  11. 11.
    Liu QY, Yao YM, Zhang SW, et al. Astragalus polysaccharides regulate T cell-mediated immunity via CD11c(high)CD45RB(low) DCs in vitro. J Ethnopharmacol. 2011;136(3):457–64.PubMedCrossRefGoogle Scholar
  12. 12.
    Clement-Kruzel S, Hwang SA, Kruzel MC, et al. Immune modulation of macrophage pro-inflammatory response by goldenseal and Astragalus extracts. J Med Food. 2008;11(3):493–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Cui R, He J, Wang B, et al. Suppressive effect of Astragalus membranaceus Bunge on chemical hepatocarcinogenesis in rats. Cancer Chemother Pharmacol. 2003;51(1):75–80.PubMedCrossRefGoogle Scholar
  14. 14.
    McCulloch M, See C, Shu XJ, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006;24(3):419–30.PubMedCrossRefGoogle Scholar
  15. 15.
    Cassileth BR, Rizvi N, Deng G, et al. Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients. Cancer Chemother Pharmacol. 2009;65(1):67–71.PubMedCrossRefGoogle Scholar
  16. 16.
    Yang AK, He SM, Liu L, et al. Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr Med Chem. 2010;17(16):1635–78.PubMedCrossRefGoogle Scholar
  17. 17.
    Zou YH, Liu XM. Effect of astragalus injection combined with chemotherapy on quality of life in patients with advanced non-small cell lung cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003;23(10):733–5.PubMedGoogle Scholar
  18. 18.
    Duan P, Wang ZM. Clinical study on effect of Astragalus in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002;22(7):515–7.PubMedGoogle Scholar
  19. 19.
    Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 2000;18(2):163–73.PubMedCrossRefGoogle Scholar
  20. 20.
    Schiller JH, Harrington D, Belani CP, Eastern Cooperative Oncology Group, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.PubMedCrossRefGoogle Scholar
  22. 22.
    Nobili S, Lippi D, Witort E, Capaccioli S, et al. Natural compounds for cancer treatment and prevention. Pharmacol Res. 2009;59(6):365–78.PubMedCrossRefGoogle Scholar
  23. 23.
    Ma XQ, Shi Q, Duan JA, et al. Chemical analysis of Radix Astragali (Huangqi) in China: a comparison with its adulterants and seasonal variations. J Agric Food Chem. 2002;50(17):4861–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Li Guo
    • 1
  • Shu-Ping Bai
    • 1
  • Ling Zhao
    • 1
  • Xiao-Hong Wang
    • 1
  1. 1.The Fifth Department of OncologyThird Affiliated Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations